Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines

Optimizing Early Sequencing and Treatment in MMПодробнее

Optimal treatment sequencing in multiple myelomaПодробнее

Sequencing of Antibodies to Treat Daratumumab ResistanceПодробнее

Patient Reported Outcomes Supports Addition of Daratumumab in Multiple Myeloma TreatmentПодробнее

Should every myeloma patient receive first-line daratumumab?Подробнее

Cassiopeia: analysis of daratumumab maintenance for myelomaПодробнее

Rationale for Selinexor Treatment in Daratumumab-Refractory Multiple Myeloma PatientsПодробнее

Optimal treatment sequencing for relapsed/refractory myelomaПодробнее

Daratumumab and isatuximab in the treatment of multiple myelomaПодробнее

Daratumumab in the treatment of MM with high-risk cytogeneticsПодробнее

Long-Term Efficacy of Daratumumab-Based Regimen in Multiple MyelomaПодробнее

Optimizing management of the high-risk myeloma patientПодробнее

How should smoldering multiple myeloma be monitored?Подробнее

What treatment is recommended for a newly diagnosed patient?Подробнее

Unravelling Treatment Options in Multiple Myeloma CareПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairmentПодробнее

Optimizing multiple myeloma treatmentПодробнее

Treatment selection and sequencing for multiple myelomaПодробнее